AU2156900A - Ribavirin-interferon alfa induction hcv combination therapy - Google Patents

Ribavirin-interferon alfa induction hcv combination therapy

Info

Publication number
AU2156900A
AU2156900A AU21569/00A AU2156900A AU2156900A AU 2156900 A AU2156900 A AU 2156900A AU 21569/00 A AU21569/00 A AU 21569/00A AU 2156900 A AU2156900 A AU 2156900A AU 2156900 A AU2156900 A AU 2156900A
Authority
AU
Australia
Prior art keywords
ribavirin
induction
combination therapy
interferon alfa
hcv combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21569/00A
Other languages
English (en)
Inventor
Janice K. Albrecht
Paul W. Glue
Carlos Olgierd Stalgis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2156900A publication Critical patent/AU2156900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU21569/00A 1998-12-18 1999-12-16 Ribavirin-interferon alfa induction hcv combination therapy Abandoned AU2156900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21587598A 1998-12-18 1998-12-18
US09215875 1998-12-18
PCT/US1999/027934 WO2000037097A1 (en) 1998-12-18 1999-12-16 Ribavirin-interferon alfa induction hcv combination therapy

Publications (1)

Publication Number Publication Date
AU2156900A true AU2156900A (en) 2000-07-12

Family

ID=22804763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21569/00A Abandoned AU2156900A (en) 1998-12-18 1999-12-16 Ribavirin-interferon alfa induction hcv combination therapy

Country Status (4)

Country Link
AR (1) AR022116A1 (es)
AU (1) AU2156900A (es)
PE (1) PE20001386A1 (es)
WO (1) WO2000037097A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
EP1795206A4 (en) 2004-08-11 2009-07-22 Chugai Pharmaceutical Co Ltd MEDICAMENT FOR THE TREATMENT OF HCV OR THE PREVENTION OF HCV INFECTION
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
KR20090021163A (ko) * 2006-05-16 2009-02-27 도쿄 메트로폴리탄 오거니제이션 포 메디칼 리서치 Ｈｃｖ 감염증을 치료 또는 예방하기 위한 의약 조성물
WO2008116919A1 (en) * 2007-03-27 2008-10-02 4Sc Ag Pharmaceutical composition comprising a cytokine
EP1977759A1 (en) * 2007-03-27 2008-10-08 4Sc Ag Pharmaceutical composition comprising a cytokine
WO2009046369A2 (en) * 2007-10-05 2009-04-09 Medtronic, Inc. Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
WO2010061881A1 (ja) 2008-11-26 2010-06-03 中外製薬株式会社 Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
EP1136075B1 (en) * 1997-09-21 2003-01-15 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
PE20001386A1 (es) 2000-12-14
AR022116A1 (es) 2002-09-04
WO2000037097A1 (en) 2000-06-29

Similar Documents

Publication Publication Date Title
AU2157000A (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
EG24678A (en) Combination therapy
AU3938099A (en) Portable induction heater
HK1052878A1 (zh) 利巴傳林-聚乙二醇化干擾素α：丙型肝炎病毒的聯合治療
GB9804885D0 (en) Therapeutic combination
EP1124578A4 (en) NEW IMMUNADJUVANZIA
IL127306A0 (en) Combination therapy
KR20010012987A (ko) 마사지 기계
AU2156900A (en) Ribavirin-interferon alfa induction hcv combination therapy
GB9816556D0 (en) Therapy
AU131414S (en) Electric cooker
IL125083A0 (en) Cooker kit assembly
GB2326521B (en) Magnetron
EP1047099A4 (en) MAGNETRON
AU3156599A (en) Induction heating
GB2339888B (en) Induction furnace
EP0962706A4 (en) ELECTRIC COOKER
GB2330942B (en) Magnetron
GB2337324B (en) Cooker
GB9826367D0 (en) Organism
AU1662800A (en) Electric sauna stove
GB9806039D0 (en) Therapy
GB2348747B (en) Cooking hobs
GB2357331B (en) Induction heating
GB9814858D0 (en) The "Maria" hob cover

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase